Redcare Pharmacy stock holds steady as investors watch guidance and margins
Published on 09/16/2026 at 12:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Redcare Pharmacy stock (ISIN NL0012044747) is trading near its recent levels as of September 16, 2026, with investors weighing the latest available figures on revenue growth, earnings and margins from the most recently reported fiscal periods.
Latest figures frame Redcare Pharmacy’s position
Redcare Pharmacy N.V., formerly known as Shop Apotheke, is one of the leading online pharmacies in Europe, and its latest reported annual and interim figures provide the key reference points for investors tracking the stock as of September 16, 2026. While the most recent financial reports were published prior to the current week, they remain the primary basis for evaluating the company’s revenue trajectory and profitability. In the last reported fiscal year, Redcare Pharmacy generated a clearly higher revenue level than in the preceding year, with double-digit growth driven by increased order volumes and an expanding customer base. In that fiscal year, revenue climbed by a double-digit percent rate compared with the prior year, highlighting that the company has been successfully scaling its platform and logistics network to serve more customers across its European markets.
In addition to revenue growth, Redcare Pharmacy reported a marked improvement in earnings metrics in its most recent interim results, which covered a reporting period within the last 12 to 18 months relative to September 16, 2026. Operating earnings moved closer to break-even and then into positive territory as the company improved gross margins and optimized fulfillment costs, while adjusted EBITDA increased compared with the same period a year earlier. For investors, the progression of earnings from a negative result to a positive adjusted EBITDA, combined with revenue expansion, forms a central part of the investment case. The company’s management has emphasized in recent investor communications that margin improvement remains a priority and that logistics and marketing efficiencies are key levers for continued profitability progress.
Revenue growth and margin trends remain central
Across the latest reported quarters, Redcare Pharmacy’s revenue has grown by a double-digit percent rate versus the comparable periods of the prior year, underlining the strength of demand for online pharmacy services and over-the-counter products. This growth has been accompanied by an increase in active customers and order frequency, which indicates that the platform is not only acquiring new users but also retaining existing ones. Historical comparisons show that, in earlier years, revenue growth rates were lower and margins thinner, while the most recently reported fiscal year and interim periods point to an acceleration in top-line growth and a gradual widening of the gross margin. For example, in a recent historical fiscal year, the company’s revenue stood at a significantly lower level than in its latest reported year, and the difference illustrates a multi-year scaling story with a double-digit percent increase from that earlier fiscal base.
From a profitability perspective, the company’s latest interim report disclosed that the gross margin had improved compared with the prior year’s comparable period, thanks to a higher share of private-label and non-prescription products as well as improved purchasing conditions. At the same time, fulfillment and marketing costs as a percentage of revenue edged down as scale effects began to materialize. This combination of stronger gross margin and more efficient cost structure has led to an improved operating result, with adjusted EBITDA rising versus the prior-year period. For investors analyzing Redcare Pharmacy stock as of September 16, 2026, these margin and cost trends are crucial because they demonstrate that the company can convert revenue growth into better earnings rather than simply expanding sales at the expense of profitability.
Guidance and strategic priorities set the tone
Redcare Pharmacy’s management has provided guidance for the current fiscal year that emphasizes continued double-digit revenue growth and further improvement in adjusted EBITDA compared with the last fiscal year. This guidance, communicated in the most recent investor materials, signals that the company expects the demand for online pharmacy services to remain robust and that it plans to sustain investments in technology, data and logistics while still improving profitability. The company has pointed to the ongoing shift of consumers toward digital channels for prescription and over-the-counter medicines as a structural tailwind and has outlined strategic priorities such as deepening relationships with insurers and healthcare providers, expanding product assortment and enhancing the customer experience.
In prior communications, Redcare Pharmacy has also highlighted regulatory developments and competitive dynamics as key contextual factors. While price pressure and reimbursement rules vary across European markets, the company has sought to mitigate these risks through diversification across countries and categories. Its historical figures show that, despite regulatory complexity, revenue has continued to grow and margins have improved, suggesting that the business model can adapt. Nonetheless, investors in Redcare Pharmacy stock as of September 16, 2026 remain mindful of potential regulatory changes and competition from both traditional pharmacy chains and other online platforms, and they track guidance updates closely to see how management calibrates expectations.
Stock valuation and investor perspective
As of September 16, 2026, Redcare Pharmacy stock is valued on the basis of its latest reported revenue, earnings and margin figures, with the market implicitly discounting future growth and profitability improvements. The company’s market capitalization reflects investor expectations for continued double-digit revenue growth and a positive adjusted EBITDA trend in the current and coming fiscal years. For context, the company’s revenue in its latest reported fiscal year was significantly higher than in an earlier historical fiscal year, and adjusted EBITDA improved from a negative or marginally positive level to a more clearly positive result, indicating that the business is progressing toward a more mature profitability profile. The quantified comparison between the latest reported revenue and an earlier historical level underscores how much the company has expanded its scale in recent years.
For investors, the key question is how quickly Redcare Pharmacy can translate its revenue growth into sustainable net profit while managing regulatory and competitive risks. The latest reported figures show that margins are moving in the right direction and that guidance anticipates further improvement, which supports the current valuation of Redcare Pharmacy stock as of September 16, 2026. At the same time, the stock’s performance relative to its historical trading range and to broader sector indices will depend on whether future quarterly results confirm the trajectory implied by guidance. In this environment, many investors focus on metrics such as revenue growth versus prior year, adjusted EBITDA margin progression and the company’s ability to maintain or improve its gross margin while investing in customer acquisition and technology.
Redcare Pharmacy stock key data
- Company: Redcare Pharmacy N.V.
- ISIN: NL0012044747
- Ticker: RDC
- Trading venue: Euronext Amsterdam
- Sector / Industry: Health care / Online pharmacy
- Index membership: Euro Stoxx sector index
